Resistant starch supplementation attenuates inflammation in hemodialysis patients: a pilot study.

Abstract

In chronic kidney disease (CKD) patients, dysbiosis is associated with inflammation and cardiovascular risk, so many nutritional strategies are being studied to reduce these complications. Resistant starch (RS) can be considered a prebiotic that promotes many benefits, including modulation of gut microbiota which is linked to immune-modulatory effects. The aim of this study was to evaluate the effects of RS supplementation on proinflammatory cytokines in CKD patients on hemodialysis (HD). A double-blind, placebo-controlled, randomized trial was conducted with sixteen HD patients (55.3 ± 10.05years, body mass index (BMI) 25.9 ± 5.42kg/m2, 56% men, time on dialysis 38.9 ± 29.23months). They were allocated to the RS group (16g RS/day) or placebo group (manioc flour). The serum concentration of ten cytokines and growth factors was detected through a multiparametric immunoassay based on XMap-labeled magnetic microbeads (Luminex Corp, USA) before and after 4weeks with RS supplementation. After RS supplementation, there was a reduction of Regulated upon Activation, Normal T-Cell Expressed and Secreted (p < 0.001), platelet-derived growth factor (two B subunits) (p = 0.014) and interferon-inducible protein 10 (IP-10) (p = 0.027). The other parameters did not change significantly. This preliminary result indicates that RS may contribute to a desirable profile of inflammatory markers in CKD patients.